alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2015155EN.01004004.xml

| 11.5.2015 | EN | Official Journal of the European Union | C 155/40 |
| --- | --- | --- | --- |

11.5.2015

EN

Official Journal of the European Union

C 155/40

---

Order of the General Court of 16 March 2015 — Fritz Winter Eisengießerei v Commission

(Case T-310/14) (1)

1

(2015/C 155/58)

Language of the case: German

The President of the Third Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 223, 14.7.2014.

1

---
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.3850 Carotid sinus nerve stimulator. ( a ) *Identification.* A carotid sinus nerve stimulator is an implantable device used to decrease arterial pressure by stimulating Hering's nerve at the carotid sinus.
( b ) *Classification.* Class III (premarket approval).
( c ) *Date PMA or notice of completion of a PDP is required.* A PMA or a notice of completion of a PDP is required to be filed with the Food and Drug Administration on or before December 26, 1996 for any carotid sinus nerve stimulator that was in commercial distribution before May 28, 1976, or that has, on or before December 26, 1996 been found to be substantially equivalent to a carotid sinus nerve stimulator that was in commercial distribution before May 28, 1976. Any other carotid sinus nerve stimulator shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
[45 FR 7907, Feb. 5, 1980, as amended at 52 FR 17736, May 11, 1987; 61 FR 50706, Sept. 27, 1996]
§ 74.2203 FD&C Green No. 3. ( a ) *Identity and specifications.* The color additive FD&C Green No. 3 shall conform in identity and specifications to the requirements of § 74.203(a)(1) and (b).
( b ) *Uses and restrictions.* The color additive FD&C Green No. 3 may be safely used for coloring cosmetics generally in amounts consistent with current good manufacturing practice.
( c ) *Labeling.* The label of the color additive shall conform to the requirements of § 70.25 of this chapter.
( d ) *Certification.* All batches of FD&C Green No. 3 shall be certified in accordance with regulations in part 80 of this chapter.
[47 FR 52144, Nov. 19, 1982]
**Exhibit 32.1**

 

**CERTIFICATION PURSUANT TO**

 

**18 U.S.C. SECTION 1350,**

 

**AS ADOPTED PURSUANT TO**

 

**SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

 

In connection with theQuarterly Report on Form 10-Q of Ebix, Inc. (the “Company”) for the periodended March 31, 2005 as filed with the Securities and Exchange Commission onthe date hereof (the “Report”), I, Robin Raina, Chief Executive Officer of theCompany, certify, pursuant to 18 U.S.C. 1350, as adopted pursuant to 906 of theSarbanes-Oxley Act of 2002, that:

 

1. The Report fully complieswith the requirements of section 13(a) or 15(d) of the Securities ExchangeAct of 1934; and

 

2. The information contained inthe Report fairly presents, in all material respects, the financial conditionand results of operations of the Company.

 

 
| By:                      | /s/ Robin  Raina |   |
|--------------------------|------------------|--------|
|                     |             |
| Name:                    | Robin Raina      |   |
|                     |             |
| Chief  Executive Officer |             |
|                     |             |
| May 12, 2005             |             |
|                          |                  |        |  |

 

----
Editorial Note on Part 864
Editorial Note: Nomenclature changes to part 864 appear at 73 FR 35341, June 23, 2008.

§ 864.9175 Automated blood grouping and antibody test system. ( a ) *Identification.* An automated blood grouping and antibody test system is a device used to group erythrocytes (red blood cells) and to detect antibodies to blood group antigens.
( b ) *Classification.* Class II (performance standards).
[45 FR 60641, Sept. 12, 1980]
Exhibit





Exhibit 10.2
Confidential Treatment Requested by Momenta Pharmaceuticals, Inc.



                    	
		
	CSL Limited
	T   +613 9389 1911

	45 Poplar Road Parkville
	F   +613 9389 1434

	Victoria 3052 Australia
	www.csl.com.au






CSLTM 


4 January 2017
    
Momenta Pharmaceuticals, Inc. 
675 West Kendall Street 
Cambridge, MA, 02142
United States
Attention: Chief Executive Officer


Dear Sirs,
We, as the ultimate 100% shareholder of CSL  Behring Recombinant Facility AG ("the Company") as of the date of this letter, confirm that it is [***] to [***] be [***] to [***] the [***] to [***] any Affiliate to whom obligations may be delegated or assigned to fulfil its obligations  under  the License and Option Agreement  between  it and Momenta  Pharmaceuticals , Inc. ("Agreement")
[***] to [***] the [***] of [***] and [***] to the [***] to [***] the [***] the [***] and [***] the [***].  This guarantee is provided for a period of [***] from [***] the Agreement.  [***] the [***] be [***] to [***] to [***] that [***] is [***] and [***] to [***] the [***] to [***] be [***] the [***] be [***] to [***] a [***] on [***] the [***] as [***].
You will be informed immediately in the event that circumstances change in a manner such that CSL Limited is no longer able to continue to provide such [***].
I confirm that I am authorised to provide these assurances on behalf of CSL Limited.
/s/ David Lamont
David Lamont
Chief Financial Officer


For and on behalf of CSL Limited




CSL Limited ABN 99 051 588 348        


Confidential Portions of this Exhibit marked as [***] have been omitted pursuant to a request for confidential treatment and have been filed separately with the Securities and Exchange Commission.
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.4900 Support gel. ( a ) *Identification.* A support gel for clinical use is a device that consists of an agar or agarose preparation that is used while measuring various kinds of, or parts of, protein molecules by various immunochemical techniques, such as immunoelectrophoresis, immunodiffusion, or chromatography.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 54 FR 25047, June 12, 1989; 66 FR 38792, July 25, 2001]
39109, 39110.

#### WILKES v. SHEPPARD; and *vice versa.*

Decided October 27, 1961.

*711*Jones & Douglas, Paul J. Jones, Jr.,*for plaintiff in error.

*Larsen ■& Larsen, W. W. Larsen,*contra.

Felton, Chief Judge.

The parties stipulated that the plaintiff would testify that the dog sued for belonged to him. Since there was no evidence contradicting this fact, the court did not err in directing a verdict in favor of the plaintiff for the dog.

The questions concerning the motion to dismiss the defendant’s plea in abatement and plea of setoff can be answered together. The court did not err in striking the plea in abatement *712for the same reason that he erred in refusing to dismiss the plea of setoff or counter-claim. The plea in bar and the plea of set-off, or counter-claim, involved a claim which could only be based on the theory of implied contract to pay the defendant, assuming but not deciding that such a claim could be sustained. What the court stated in *Powers v. Wren,*198 Ga. 316, 319 (31 SE2d 713) seems to be sufficient to cover the issues' raised by the two motions to dismiss. The court in that case stated: “The present action is a trover suit. The gist of such an action is conversion. *Southern Express Co. v. Sinclair,*130 Ga. 372 (60 SE 849). It is one brought against a wrongdoer and sounds in tort. The cross-action was on contract. The two claims were not of a similar nature. This was a sufficient reason to strike the cross-action. *McArthur v. Wilson,*13 Ga. App. 502 (79 SE 374); *Hecht v. Snook & Austin Furniture Co.,*114 Ga. 921 (41 SE 74). . . With the one exception contained in the *Code,*§ 107-102, which is not here applicable, no. counter-claim is permitted to be urged in an action of trover, in the absence of exceptional circumstances sufficient to give rise to equitable relief. *Barrow v. Mallory,*89 Ga. 76 (14 SE 878); *Harden v. Lang,*110 Ga. 392, 396 (36 SE 100). The section above cited, codified from the act approved August 15, 1903 (Ga. L. 1903, p. 84), which in certain instances permits a defendant to plead a set-off or to recoup in damages, is limited to suits brought to recover personal property where the vendor retains title. This is not that kind of a case.”

The court did not err in directing a verdict in favor of the plaintiff for the dog sued for. The court did not err in dismissing the plea in abatement but did err in overruling the motion to dismiss the plea of setoff or cross-action. The judgment in favor of the plaintiff for the dog sued for shall remain in effect. The court is directed to dismiss the plea of setoff or cross-action and this will, under the circumstances of this case, terminate the litigation. In view of the ruling on the motion to dismiss the plea of setoff or cross-action, it is not necessary to rule on the exception to the overruling of the motion for a new trial.

*Judgment reversed on the main bill of exceptions and affirmed on the cross-bill.*

*Bell and Hall, JJ., concur.*
# C_2015127EN.01003903.xml

| 20.4.2015 | EN | Official Journal of the European Union | C 127/39 |
| --- | --- | --- | --- |

20.4.2015

EN

Official Journal of the European Union

C 127/39

---

Order of the General Court of 27 January 2015 — Richard Anton v ECHA

(Case T-208/14) (1)

1

(2015/C 127/54)

Language of the case: English

The President of the Sixth Chamber has ordered that the case be removed from the register.

---

(1)  OJ C 202, 30.6.2014.

1

---
EXHIBIT 32.2SECTION 1350 CERTIFICATION     I, Edward P. Smolyansky, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant toSection 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Lifeway Foods, Inc.(the “Company”) on Form 10-QSB/A for three-month period ended June 30, 2006:     (1) Fully complies with the requirements of section 13(a) or 15(d) of the SecuritiesExchange Act of 1934; and     (2) that the information contained in the report fairly presents, in all materialrespects, the financial condition and results of operations of the Company.     This written statement is being furnished to the Securities and Exchange Commission as anexhibit to such Form 10-QSB. A signed original of this written statement required by Section 906has been provided to the Company and will be retained by the Company and furnished to theSecurities and Exchange Commission or its staff upon request.Date:May 14, 2007       /s/ Edward P. Smolyansky     Chief Financial and Accounting Officerand Treasurer
Exhibit 11

<TABLE>
<CAPTION>
                                   CNS, INC.
           COMPUTATION OF NET INCOME (LOSS) PER SHARE OF COMMON STOCK
                                  (unaudited)

                                                              1995           1994             1995           1994
<S>                                                        <C>             <C>            <C>            <C>        
Income (loss) from continuing
operations before income taxes                            $1,510,547      $(631,303)     $11,461,672    $(1,539,290)

Income tax provision                                         150,000              0        1,060,000              0

Income (loss) from continuing operations                   1,360,547       (631,303)      10,401,672     (1,539,290)

Income (loss) from operations of
discontinued sleep division (less
applicable income tax benefit of
$259,000 and $0 at September 30,
1995 and 1994, respectively).                                      0         36,694         (459,901)        43,762

Gain on disposal of sleep division (less
applicable income taxes of $690,000
and $0 at September 30, 1995 and
1994 respectively).                                                0              0        1,225,890              0

Income from discontinued operations                                0         36,694          765,989         43,762


Net income (loss)                                         $1,360,547      $(594,609)     $11,167,661    $(1,495,528)


Income (loss) per common and
common equivalent share
  From continuing operations before
  income tax                                                     .08           (.04)             .62           (.10)
  From income tax on continuing operations                      (.01)             0             (.05)             0

  From continuing operations                                     .07           (.04)             .57           (.10)

  From discontinued operations (sleep div.)                        0              0             (.03)             0
  From gain on disposal of sleep division                          0              0              .07              0

  From discontinued operations, net                                0              0              .04              0

Net income (loss) per common and
common equivalent share                                   $      .07      $    (.04)     $       .61    $      (.10)

Weighted average number of
common and common equivalent
shares outstanding                                        18,657,086     16,753,952       18,342,901     15,357,218

</TABLE>
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          MAR-31-1997
<PERIOD-END>                               DEC-31-1996
<CASH>                                         940,000
<SECURITIES>                                         0
<RECEIVABLES>                                1,932,000
<ALLOWANCES>                                         0
<INVENTORY>                                  2,424,000
<CURRENT-ASSETS>                             5,519,000
<PP&E>                                       1,302,000
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                               9,244,000
<CURRENT-LIABILITIES>                        2,206,000
<BONDS>                                        450,000
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                    19,345,000
<OTHER-SE>                                (12,757,000)
<TOTAL-LIABILITY-AND-EQUITY>                 9,244,000
<SALES>                                              0
<TOTAL-REVENUES>                             6,871,000
<CGS>                                                0
<TOTAL-COSTS>                                5,107,000
<OTHER-EXPENSES>                             3,247,000
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                           (193,000)
<INCOME-PRETAX>                            (1,290,000)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                        (1,290,000)
<DISCONTINUED>                                (62,000)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                               (1,352,000)
<EPS-PRIMARY>                                   (0.25)
<EPS-DILUTED>                                   (0.25)
        

</TABLE>
#### § 820.65 Traceability.

Each manufacturer of a device that is intended for surgical implant into the body or to support or sustain life and whose failure to perform when properly used in accordance with instructions for use provided in the labeling can be reasonably expected to result in a significant injury to the user shall establish and maintain procedures for identifying with a control number each unit, lot, or batch of finished devices and where appropriate components. The procedures shall facilitate corrective action. Such identification shall be documented in the DHR.
Editorial Note on Part 878
Editorial Note: Nomenclature changes to part 878 appear at 73 FR 35341, June 23, 2008.

§ 878.5000 Nonabsorbable poly(ethylene terephthalate) surgical suture. ( a ) *Identification.* Nonabsorbable poly(ethylene terephthalate) surgical suture is a multifilament, nonabsorbable, sterile, flexible thread prepared from fibers of high molecular weight, long-chain, linear polyesters having recurrent aromatic rings as an integral component and is indicated for use in soft tissue approximation. The poly(ethylene terephthalate) surgical suture meets U.S.P. requirements as described in the U.S.P. Monograph for Nonabsorbable Surgical Sutures; it may be provided uncoated or coated; and it may be undyed or dyed with an appropriate FDA listed color additive. Also, the suture may be provided with or without a standard needle attached.
( b ) *Classification.* Class II (special controls). The special control for this device is FDA's “Class II Special Controls Guidance Document: Surgical Sutures; Guidance for Industry and FDA.” See § 878.1(e) for the availability of this guidance document.
[56 FR 24685, May 31, 1991, as amended at 68 FR 32984, June 3, 2003]
Michigan Supreme Court Lansing, Michigan

Marilyn Kelly,
Chief Justice

Michael F. Cavanag h

Elizabeth A. Weave r

Maura D. Corriga n Robert P. Young, Jr. Stephen J. Markma n Diane M. Hathaway,

J ustices

I, Corbin R. Davis, Clerk of the Mi chigan Supreme Cour t, certify that the foregoing is a true and complete copy of the order entered at the direction of the Court.

_______________________________________ __ Clerk October 26, 2009

1019 

# Order

October 26, 2009

138374

PEOPLE OF THE STATE OF MICHIGAN, Plaintiff-Appellee,

v SC: 138374 COA: 280430 Wayne CC: 07-006795-01 COREY JONES, Defendant-Appellant.

________________ _______________ __________/

On order of the Court, the application for leave to appeal the January 20, 2009 judgment of the Court of Appeals is consid ered, and it is DENIED, because we are not persuaded that the questions presented should be reviewed by this Court.

H ATHAWAY , J., not participating. Justice Ha thaway recuses herself and will not participate in this case as sh e was the presiding trial court judge. See MCR 2.003(B).
<TABLE> <S> <C>


<ARTICLE> 5
<LEGEND>
This  schedule  contains  summary  financial   information  extracted  from  the
Consolidated  Balance Sheets  (Unaudited) as of February 2, 1997 and November 3,
1996 and the  Consolidated  Statements  of Income  (Unaudited)  for the quarters
ended  February 2, 1997 and January 28, 1996  contained in the Form 10-Q for the
quarter ended February 2, 1997, and is qualified in its entirety by reference to
such financial statements.
</LEGEND>
<MULTIPLIER> 1,000
<CURRENCY> U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          NOV-02-1997
<PERIOD-START>                             NOV-04-1996
<PERIOD-END>                               FEB-02-1997
<EXCHANGE-RATE>                                      1
<CASH>                                          12,346
<SECURITIES>                                         0
<RECEIVABLES>                                  195,443
<ALLOWANCES>                                  (13,057)
<INVENTORY>                                    465,042
<CURRENT-ASSETS>                               669,676
<PP&E>                                         118,477
<DEPRECIATION>                                (64,898)
<TOTAL-ASSETS>                                 750,083
<CURRENT-LIABILITIES>                          551,251
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                           155
<OTHER-SE>                                     195,023
<TOTAL-LIABILITY-AND-EQUITY>                   750,083
<SALES>                                        860,319
<TOTAL-REVENUES>                               860,319
<CGS>                                          804,367
<TOTAL-COSTS>                                  804,367
<OTHER-EXPENSES>                                43,064
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                 474
<INCOME-PRETAX>                                  8,128
<INCOME-TAX>                                     3,460
<INCOME-CONTINUING>                              4,668
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     4,668
<EPS-PRIMARY>                                     0.29
<EPS-DILUTED>                                     0.29
        

</TABLE>
EXHIBIT 24.1



     POWER OF ATTORNEY

     KNOW ALL MEN BY THESE PRESENTS, that Ambassadors International, Inc.,
     a Delaware corporation (the "Company"), and the undersigned officers
     and directors of the Company, individually and in their respective
     capacities indicated below, hereby make, constitute and appoint John
     A. Ueberroth and Jeffrey D. Thomas, or either of them, its and their
     true and lawful attorneys with power of substitution, to execute on
     behalf of the Company, the Form 10-KSB, including all exhibits and any
     and all amendments thereto; that John A. Ueberroth and Jeffrey D.
     Thomas, or either of them, are each granted full power and authority
     to do and perform each and every act and thing whatsoever as either
     may deem necessary or advisable to the same extent and with the same
     effect as the undersigned might or could do personally in their
     respective capacities.

     This Power of Attorney may be signed by the undersigned in as many
     counterparts as may be necessary, each of which so signed shall be
     deemed to be an original, and such counterparts together shall
     constitute one and the same instrument and notwithstanding the date of
     execution shall be deemed to bear the date as set forth below.
     Furthermore, facsimile signatures shall be deemed to have the same
     effect as original signatures.

     Dated as of the 12th day of March, 1997.

     AMBASSADORS INTERNATIONAL, INC.


     Attest:  /s/ Jeffrey D. Thomas          By:  /s/John A. Ueberroth
              -----------------------------       -------------------------
              Jeffrey D. Thomas, Secretary        John A. Ueberroth,
                                                  President and Chief
                                                  Executive Officer
                                                  (Principal Executive
                                                  Officer)

              /s/ Peter V. Ueberroth              /s/ Jeffrey D. Thomas
              -----------------------------       -------------------------
              Peter V. Ueberroth, Chairman        Jeffrey D. Thomas,
              and Director                        (Principal Financial and
                                                  Accounting Officer)

              /s/ John C. Spence                  /s/ Rafer L. Johnson
              -----------------------------       -------------------------
              John C. Spence, Director            Rafer L. Johnson,
                                                  Director

              /s/ Richard D.C. Whilden            /s/ James L. Easton
              -----------------------------       -------------------------
              Richard D.C. Whilden,               James L. Easton, Director
              Director